Trevi Therapeutics Inc. (NASDAQ: TRVI) Stock Information | RedChip

Trevi Therapeutics Inc. (NASDAQ: TRVI) Listen to this Section


$2.73
+0.1200 ( +4.60% ) 95.3K

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Market Data


Open


$2.73

Previous close


$2.61

Volume


95.3K

Market cap


$199.63M

Day range


$2.61 - $2.82

52 week range


$0.97 - $4.00

Insider Ownership Transactions

Total Amount Purchased: -285,012.00 | $ -778,082.76

Date Type Amount Purchased Purchaser
2024-06-14 Sale -30000.00 Meeker David P
2024-06-14 Sale -30000.00 Colangelo Dominick
2024-06-14 Sale -30000.00 VANLENT ANNE
2024-06-14 Sale -30000.00 Cassella James V
2024-06-14 Sale -30000.00 Mathers Edward T
2024-06-14 Sale -30000.00 Heffernan Michael Thomas
2024-05-31 Sale -59354.00 SCIASCIA THOMAS
2024-05-24 Sale -16043.00 Delfini Lisa
2024-05-22 Sale -25037.00 GOOD JENNIFER L
2024-05-14 Sale -4578.00 GOOD JENNIFER L

SEC Fillings


Form Type Description Pages Date
8-k 8K-related 13 Aug 08, 2024
10-q Quarterly Reports 66 Aug 08, 2024
4 Insider transactions 1 Jun 14, 2024
4 Insider transactions 2 Jun 14, 2024
4 Insider transactions 1 Jun 14, 2024
4 Insider transactions 1 Jun 14, 2024
4 Insider transactions 1 Jun 14, 2024
4 Insider transactions 1 Jun 14, 2024
8-k 8K-related 11 Jun 13, 2024
4 Insider transactions 1 May 31, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.